Cobas® Lumira Collection of Venous and Capillary Blood Samples for the Research, Optimization and Calibration of New Diagnostic Devices

Inclusion criteria

• Willing and able to provide written informed consent.
• Willing to comply with study procedures.
• The participant must present as one of the following cohorts (primary presenting condition):

• Cohort A - Embolism Cohort (participants presenting with symptoms indicative of thromboembolic events)
• Cohort B - Infection or Inflammation Cohort (participants presenting with symptoms indicative of infection or inflammatory disorders)
• Cohort C - Cardiovascular Cohort (participants presenting with symptoms indicative of heart failure or acute coronary syndrome)
• Cohort D - Renal Cohort (participants presenting with symptoms indicative of renal disorders)
• Cohort E - Oral Anticoagulation Cohort (participants with ongoing vitamin K antagonist therapy for at least four weeks)
• Cohort F - Diabetes Cohort (participants with suspected pre-Diabetes or diagnosed with Diabetes Mellitus Type 1 or Type 2)
• Cohort G - Lipid Cohort (participants presenting with symptoms indicative for Hypercholesterolemia )
• Cohort H - Liver Cohort (participants with symptoms indicative of hepatic disorders).

Inclusion criteria

for Cohorts A, B, C, D, E, G, and H:

• Participants ≥ 18 years of age

Inclusion criteria

for Cohort F (Diabetes Cohort):

• Participants ≥ 16 years old

Exclusion criteria

• Subjects deemed inappropriate for the study by the Principal Investigator.
• Participants who have previously been enrolled in the EVOLVE study in the past 60 days.

Exclusion criteria

for Cohort E (Oral Anticoagulation Cohort):

• Subjects who are currently taking non-vitamin K antagonist oral anticoagulants (NOACs) including but not limited to apixaban, dabigatran etexilate, edoxaban and rivaroxaban.
• Subjects who have anti-phospholipid antibody syndrome (APS)
• The participant is currently receiving or has received within the past thirty (30) days of the study visit an experimental biologic, experimental drug, or experimental device including either treatment or therapy.